Ultrasonography: Preliminary clinical study on low-intensity transcranial focused ultrasound therapy for Alzheimer's disease and stroke treatment

Research Article | Open Access

Ultrasonography(IF=4.7247,2021年)

https://pubmed.ncbi.nlm.nih.gov/33730775/

Alzheimer's disease

(Alzheimer’s disease,AD)It is a neurodegenerative disease with insidious onset and progressive development, characterized by cognitive impairment, abnormal mental behavior, and decreased social functioning. According to the World Health Organization report, approximately 50 million people worldwide suffer from dementia, with Alzheimer's disease being the most common type.

Low intensity transcranial focused ultrasound

(Transcranial Focused Ultrasound,tFUS)It is an emerging method of brain neural regulation that can activate or inhibit the electrical activity of target neurons with reversible, non-invasive, high spatial resolution, and deeper stimulation characteristics almost without increasing tissue temperature.

 

 

Article Introduction

In October 2021, the Hyeonseok Jeong team at St. Mary's Hospital in Incheon, South Korea, first investigated the effects of low-intensity tFUS on Regional Cerebral Metabolic Rate of Glucose (rCMRglu) and cognitive function in AD patients.

Highlights

1. tFUS can improve cognitive function, executive function, and memory in AD patients;
2. After tFUS intervention, the local brain glucose metabolism rate increased in AD patients.

1.Material and method

This single center prospective study has been approved by the Institutional Review Board of St. Mary's Hospital in Incheon, South Korea (OC18DESI0130). All participants and their legal guardians have signed a written informed consent form. The research team recruited four elderly AD patients aged 65-80 from the neurology department of the hospital from August 2019 to November 2019 (average age: 78.8 ± 3.3 years; including three females and one male).

Diagnostic criteria:Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV); National Institute of Neurology and Language Disorders, Stroke, Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) standards.

Exclusion criteria:Epilepsy, stroke, mixed or vascular dementia, other neurological or psychiatric disorders (based on MRI imaging), and contraindications related to magnetic resonance imaging (MRI), MRI contrast agents, or microbubble ultrasound contrast agents (MB).

Pre evaluation:This includes medical history collection, neurologists conducting physical and neurological examinations on patients, routine blood biochemistry tests, blood cell counts, lipid testing, electroencephalography, and chest X-ray examinations. In addition, patients will undergo neurophysiological tests (evaluating attention), visual spatial function tests (visual function), language learning tests (memory), and executive function tests

Target determination:The patient should be admitted 24 hours before treatment to have their physical condition checked. TFUS pre scans the patient's head using MRI and CT to determine the treatment target location (hippocampus). Using optical navigation combined with MRI structural images (T1 weighted images) to ensure that the tFUS focus is located in the patient's hippocampus.

 

▲ Figure 1. Experimental flowchart. tFUS, Transcranial focused ultrasound; MRI, Magnetic resonance imaging; CT, Computed tomography; PET, Positron emission tomography; NP, Neuropsychological testing

Parameter settings:The patient lies comfortably on the treatment chair, the operating doctor evenly smears the ultrasonic hydrogel on the contact area between the patient's ultrasonic probe and scalp, and injects 10 μ L/kg of MB into the right hippocampus of the patient within one minute by intravenous catheterization. Immediately afterwards, the patient's hippocampus was stimulated using the following ultrasound parameters: fundamental frequency (f0)=250kHz, pulse duration (TBS)=20ms, pulse repetition frequency (PRF)=2Hz, and duty cycle (DC)=4%. The average intensity of spatial peak pulses (Isppa) is 0.5-3W/cm2, and the average intensity of spatial peak times (Ispta) is 0.02-0.12W/cm2.

Prognosis:Scan the patient's head MRI 30 minutes after the end of treatment to observe changes in the brain. One day after the end of treatment, the patient underwent another MRI scan to evaluate the stimulation target rCMRglu level. Combined with neuropsychological tests, the patient's memory, executive ability, and overall cognitive function were re evaluated. Two weeks after prognosis, PET-CT will be performed on the patient to track and observe for any adverse reactions or events.

2.Experimental result

Neurophysiological tests:The results of neuropsychological tests after tFUS intervention showed that AD patients had slight improvements in overall cognitive function (MMSE), executive function, and memory.

▲ Table 1. MMSE, Mini Mental State Examination; CDR, Clinical Dementia Grading Scale; CDR-SOB, CDR Overall Functional Evaluation Scale; RCFT, Rey complex graphic testing; n/a, Not evaluated, due to the patient's inability to read or cooperate; SVLT-E, Seoul Language Learning Test - Elderly Edition; K-CWST, Korean Strut Color Word Test; COWAT, Controlled oral word association test.

Imaging examination:MRI and PET images showed that after low-intensity tFUS intervention, rCMRglu in the right superior frontal gyrus (6.6%, P<0.001), middle right cingulate gyrus (5.5%, P<0.001), and left fusiform gyrus (5.4%, P<0.001) of patients significantly increased (P=0.001).

▲Figure 2. Changes in local brain glucose metabolism rate (rCMRglu) after tFUS stimulation. Compared to baseline, there was an increase (red yellow) or decrease (blue-green) in rCMRglu in patients during follow-up. a) The coordinate system refers to the coordinate system of the Montreal Institute of Neurology.

3.Conclusion

This article suggests that the use of low-intensity transcranial focused ultrasound stimulation (tFUS) can have beneficial effects on brain glucose metabolism and cognitive function in AD patients. With its high-precision spatial resolution and significant depth penetration capability, tFUS is expected to become a novel non-invasive neural regulatory tool for regulating cortical and deep brain neurons in AD patients.